Whittier Trust Co. held its position in Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,755 shares of the medical technology company’s stock at the end of the second quarter. Whittier Trust Co.’s holdings in Stryker Corporation were worth $244,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SYK. Teachers Advisors LLC boosted its position in Stryker Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 377,336 shares of the medical technology company’s stock worth $45,209,000 after buying an additional 20,450 shares during the period. Macquarie Group Ltd. boosted its position in Stryker Corporation by 13.3% in the fourth quarter. Macquarie Group Ltd. now owns 103,000 shares of the medical technology company’s stock worth $12,341,000 after buying an additional 12,100 shares during the period. Pensionfund Sabic purchased a new position in Stryker Corporation during the first quarter worth $2,014,000. Toth Financial Advisory Corp boosted its position in Stryker Corporation by 0.6% in the first quarter. Toth Financial Advisory Corp now owns 77,031 shares of the medical technology company’s stock worth $10,141,000 after buying an additional 471 shares during the period. Finally, Pensionfund DSM Netherlands purchased a new position in Stryker Corporation during the first quarter worth $4,002,000. Institutional investors own 73.79% of the company’s stock.
Stryker Corporation (SYK) traded down 0.74% on Friday, hitting $144.29. 1,673,285 shares of the company traded hands. Stryker Corporation has a 12 month low of $106.48 and a 12 month high of $148.84. The stock’s 50-day moving average is $144.61 and its 200 day moving average is $136.38. The firm has a market capitalization of $53.97 billion, a P/E ratio of 32.21 and a beta of 0.80.
Stryker Corporation (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.51 by $0.02. The company had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.98 billion. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.39 earnings per share. Equities analysts forecast that Stryker Corporation will post $6.50 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be given a dividend of $0.425 per share. The ex-dividend date is Thursday, September 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.18%. Stryker Corporation’s dividend payout ratio is presently 37.95%.
ILLEGAL ACTIVITY WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/08/19/stryker-corporation-nysesyk-position-maintained-by-whittier-trust-co-updated-updated.html.
A number of analysts have issued reports on SYK shares. Needham & Company LLC reiterated a “sell” rating on shares of Stryker Corporation in a report on Wednesday, April 26th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $140.00 price target (up from $135.00) on shares of Stryker Corporation in a report on Wednesday, April 26th. Cowen and Company set a $150.00 price target on shares of Stryker Corporation and gave the company an “outperform” rating in a report on Wednesday, April 26th. Barclays PLC reiterated a “sell” rating and issued a $133.00 price target on shares of Stryker Corporation in a report on Thursday, April 27th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $148.00 price target (up from $135.00) on shares of Stryker Corporation in a report on Saturday, April 29th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $144.03.
In other news, insider Graham A. Mclean sold 1,124 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the completion of the sale, the insider now owns 8,983 shares in the company, valued at approximately $1,313,853.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction on Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the transaction, the insider now directly owns 88,207 shares in the company, valued at $12,909,976.52. The disclosure for this sale can be found here. Insiders have sold a total of 32,810 shares of company stock valued at $4,754,958 in the last 90 days. Insiders own 7.40% of the company’s stock.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
What are top analysts saying about Stryker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stryker Corporation and related companies.